IOL Chemicals and Pharmaceuticals Limited

NSEI:IOLCP Stock Report

Market Cap: ₹21.8b

IOL Chemicals and Pharmaceuticals Valuation

Is IOLCP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IOLCP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IOLCP (₹371.55) is trading below our estimate of fair value (₹465.67)

Significantly Below Fair Value: IOLCP is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IOLCP?

Key metric: As IOLCP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for IOLCP. This is calculated by dividing IOLCP's market cap by their current earnings.
What is IOLCP's PE Ratio?
PE Ratio21.8x
Earnings₹998.20m
Market Cap₹21.81b

Price to Earnings Ratio vs Peers

How does IOLCP's PE Ratio compare to its peers?

The above table shows the PE ratio for IOLCP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.2x
590006 Amrutanjan Health Care
42.6xn/a₹20.3b
507747 TTK Healthcare
25.3xn/a₹20.2b
530199 Themis Medicare
47.3xn/a₹25.1b
SMSPHARMA SMS Pharmaceuticals
37.5xn/a₹22.3b
IOLCP IOL Chemicals and Pharmaceuticals
21.8x27.5%₹21.8b

Price-To-Earnings vs Peers: IOLCP is good value based on its Price-To-Earnings Ratio (21.8x) compared to the peer average (38.2x).

Price to Earnings Ratio vs Industry

How does IOLCP's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$74.22m
524652 Ind-Swift
2.8xn/aUS$13.24m
No more companies available in this PE range
IOLCP 21.8xIndustry Avg. 32.7xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: IOLCP is good value based on its Price-To-Earnings Ratio (21.8x) compared to the Indian Pharmaceuticals industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is IOLCP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IOLCP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.8x
Fair PE Ratio35.7x

Price-To-Earnings vs Fair Ratio: IOLCP is good value based on its Price-To-Earnings Ratio (21.8x) compared to the estimated Fair Price-To-Earnings Ratio (35.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IOLCP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹371.55
₹471.00
+26.8%
0.8%₹475.00₹467.00n/a2
Nov ’25₹403.40
₹471.00
+16.8%
0.8%₹475.00₹467.00n/a2
Oct ’25₹474.95
₹471.00
-0.8%
0.8%₹475.00₹467.00n/a2
Sep ’25₹441.10
₹471.00
+6.8%
0.8%₹475.00₹467.00n/a2
Aug ’25₹428.55
₹471.00
+9.9%
0.8%₹475.00₹467.00n/a2
Jul ’25₹409.40
₹471.00
+15.0%
0.8%₹475.00₹467.00n/a2
Jun ’25₹359.85
₹484.00
+34.5%
1.9%₹493.00₹475.00n/a2
May ’25₹393.70
₹517.00
+31.3%
1.4%₹524.00₹510.00n/a2
Apr ’25₹378.60
₹517.00
+36.6%
1.4%₹524.00₹510.00n/a2
Mar ’25₹408.55
₹517.00
+26.5%
1.4%₹524.00₹510.00n/a2
Feb ’25₹442.00
₹518.00
+17.2%
1.5%₹526.00₹510.00n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹944.45

7D

-3.5%

1Y

18.1%

Solara Active Pharma Sciences

₹36.4b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

SOLARAPP

₹468.50

7D

-5.7%

1Y

n/a

Venus Remedies

₹4.0b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹302.65

7D

-4.6%

1Y

-12.4%